Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF?
NCT04665375
·
clinicaltrials.gov ↗
PHASE4
Phase
TERMINATED
Status
4
Enrollment
OTHER
Sponsor class
Stopped
enrollment futility
Conditions
Hiv
Weight Gain
Interventions
DRUG:
DOR/3TC/TDF
Sponsor
University Health Network, Toronto
Collaborators
[object Object]